Immunization of Rhesus monkeys with the conjugate vaccine IGN402 induces an IgG immune response against carbohydrate and protein antigens, and cancer cells

Vaccine

Volumn 24, Issue 13, 2006, Pages 2349-2357

  Kircheis, Ralf ^a   Vondru, Petra ^a   Zinöcker, Irene ^a   Häring, Daniela ^a   Nechansky, Andreas ^a   Loibner, Hans ^a   Mudde, Geert C ^a  

^a Igeneon AG   (Austria)

Author keywords

Carbohydrate; Cytokine release; Immune response; SialylTn

Indexed keywords

ALUMINUM HYDROXIDE; CANCER ANTIBODY; CANCER VACCINE; CARBOHYDRATE ANTIGEN; EDRECOLOMAB; GAMMA INTERFERON; IGN 402; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; QS 21; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BINDING; DRUG FORMULATION; DRUG TOLERABILITY; HYDROGEL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CANCER VACCINES; CYTOKINES; IMMUNIZATION; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; MACACA MULATTA; RABBITS; SAPONINS; T-LYMPHOCYTES; VACCINES, CONJUGATE;

EID: 33344479308     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.11.059     Document Type: Article

References (20)

1. P.Y.S. Fung, M. Madej, R.R. Koganty, and B.M. Longenecker Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate Cancer Res 50 1990 4308 4314
2. A. Singhal, M. Fohn, and S.-I. Hakomori Induction of a α-N-acetylgalactosamine-O-serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice Cancer Res 51 1991 1406 1411
3. S. Zhang, L.A. Walberg, F. Helling, G. Ragupathi, S. Adluri, and K.O. Lloyd Augmenting the immunogenicity of synthetic MUC-1 vaccines in mice Cancer Res 55 1996 3364 3368
4. H. Zhang, S. Zhang, N.K. Cheung, G. Ragupathi, and P.O. Livingston Antibodies can eradicate cancer micrometastases Cancer Res 58 1998 2844 2849
5. P.O. Livingston, G.Y.C. Wong, S. Adluri, Y. Tao, M. Padavan, and R. Parente Improved survival in AJCC stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside J Clin Oncol 12 1994 1036 1044
6. G.D. MacLean, M.A. Reddish, R.R. Koganty, and B.M. Longenecker Antibodies against mucin-associated SialylTn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine J Immunother 19 1996 59 68
7. S.H. Itzkowitz, M. Yuan, C.K. Montgomery, T. Kjeldsen, H.K. Takahashi, and W.L. Bigbee Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer Cancer Res 49 1989 197 204
8. S. Zhang, S.H. Zhang, C. Cordon-Cardo, V.E. Reuter, A.K. Singgal, and K.O. Lloyd Selection of tumor antigens as targets for immune attack using immunohistochemistry. II. Blood group-related antigens Int J Cancer 73 1997 50 56
9. S. Zhang, L.A. Walberg, S. Ogata, S.H. Itzkowitz, R.R. Koganty, and M. Reddish Immune sera and monoclonal antibodies define two configurations for the sialylTn tumor antigen Cancer Res 55 1995 3364 3368
10. S.H. Itzkowitz, E.J. Bloom, W.A. Kokal, G. Modin, S. Hakomori, and Y.S. Kim Sialosyl-Tn: a novel mucin antigen associated with prognosis in colorectal cancer patients Cancer 66 1990 1960 1966
11. J.L. Werther, S. Rivera-MacMurray, H. Bruckner, M. Tatematsu, and S.H. Itzkowitz Mucin-associated sialosyl-Tn antigen expression in gastric cancer correlates with an adverse outcome Br J Cancer 69 1994 613 616
12. G. Ragupathi, F. Koide, N. Santhyan, E. Kagan, M. Spassova, and W. Bornmann A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancer Cancer Immunol Immunother 52 2003 608 616
13. G. Ragupathi, D.M. Coltart, L.J. Williams, F. Koide, E. Kagan, and J. Allen On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines Proc Natl Acad Sci USA 99 2002 13699 13704
14. J. Fagerberg, P. Ragnhammar, M. Liljefors, A.L. Hjelm, H. Mellstedt, and J.E. Frodin Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A Cancer Immunol Immunother 42 1996 81 87
15. J. Fagerberg, J.E. Frodin, H. Wigzell, and H. Mellstedt Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy? Cancer Immunol Immunother 37 1993 264 270
16. G. Riethmuller, E. Schneider-Gadicke, G. Schlimok, W. Schmiegel, R. Raab, and K. Hoffken Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study group Lancet 343 1994 1172 1174
17. Settaf A, Salzberg M, Groiss F, Eller N, Schuster M, Himmler G, Kundi M, Eckert H, Loibner H. A randomized placebo-controlled Phase II study with the cancer vaccine IGN101 in patients with epithelial cancers. In: Proceedings of the iSBTc 19th Annual Meeting, San Franscisco, 4-7 November 2004.
18. G. Ragupathi, L. Howard, S. Capello, R.R. Koganthy, D. Qiu, and B.M. Longenecker Vaccines prepared with SialylTn and SialylTn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and SialylTn-positive tumor cells Cancer Immunol Immunother 48 1999 1 8
19. E. Kagan, G. Ragupathi, S.S. Yi, C.A. Reis, J. Gildersleeve, and D. Kahne Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn Cancer Immunol Immunother 54 2005 424 430
20. Kircheis R, Vondru P, Nechansky A, Ohler R, Loibner H, Himmler G, et al. SialylTn-mAb17-1A carbohydrate-protein conjugate vaccine: effect of coupling density and presentation of SialylTn, Bioconjug Chem 2005:16;1519-28 (in press).